tiprankstipranks
Jupiter Life Line Hospitals Ltd. (IN:JLHL)
:JLHL
India Market
Want to see IN:JLHL full AI Analyst Report?

Jupiter Life Line Hospitals Ltd. (JLHL) AI Stock Analysis

0 Followers

Top Page

IN:JLHL

Jupiter Life Line Hospitals Ltd.

(JLHL)

Select Model
Select Model
Select Model
Neutral 66 (OpenAI - 5.2)
Rating:66Neutral
Price Target:
₹1,449.00
▼(-6.07% Downside)
Action:Reiterated
Date:05/19/26
The score is driven primarily by improved fundamentals (growth, profitability turnaround, and a strengthened balance sheet), offset by materially negative recent free cash flow and some 2026 margin compression. Technicals are supportive with positive momentum, but valuation is a key constraint due to the high P/E and low dividend yield.
Positive Factors
Consistent multi-year revenue growth
Multi-year top-line scaling (2021–2026) and reported ~18.9% revenue growth indicate durable demand and expanding patient volumes. Sustained revenue growth supports fixed-cost absorption, capacity leverage, and provides a stable base for margin recovery and reinvestment over the next 2–6 months.
Negative Factors
Sharply negative free cash flow
Despite positive operating cash flow, free cash flow is sharply negative due to heavy capex and/or working-capital absorption. Persistent negative FCF erodes liquidity after reinvestment, forces external financing, and raises execution risk if cash burn continues while expansion ramps.
Read all positive and negative factors
Positive Factors
Negative Factors
Consistent multi-year revenue growth
Multi-year top-line scaling (2021–2026) and reported ~18.9% revenue growth indicate durable demand and expanding patient volumes. Sustained revenue growth supports fixed-cost absorption, capacity leverage, and provides a stable base for margin recovery and reinvestment over the next 2–6 months.
Read all positive factors

Jupiter Life Line Hospitals Ltd. (JLHL) vs. iShares MSCI India ETF (INDA)

Jupiter Life Line Hospitals Ltd. Business Overview & Revenue Model

Company Description
Jupiter Life Line Hospitals Limited, a multi-specialty hospital, provides health care services under the Jupiter brand in India. The company provides treatments in the areas of bariatric surgery, breast care center, cardiac surgery, cardiology, ch...
How the Company Makes Money
JLHL primarily makes money by delivering hospital-based healthcare services to patients and billing for these services through a mix of self-pay patients, private/commercial insurance, and government/third-party payer programs (where applicable). ...

Jupiter Life Line Hospitals Ltd. Financial Statement Overview

Summary
Strong multi-year revenue growth and a clear shift from 2021 losses to sustained profitability, with a much improved leverage profile by 2024–2026. The main drag is cash-flow quality: free cash flow turned sharply negative in 2025 and worsened in 2026, alongside some 2026 margin compression and a step-up in total debt.
Income Statement
78
Positive
Balance Sheet
72
Positive
Cash Flow
56
Neutral
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue13.93B15.00B12.62B10.70B8.93B7.33B
Gross Profit11.31B8.69B10.31B8.55B7.11B4.07B
EBITDA3.63B3.43B3.25B2.61B2.06B1.50B
Net Income1.98B1.94B1.93B1.77B729.05M511.28M
Balance Sheet
Total Assets20.23B23.83B19.05B12.81B9.86B9.09B
Cash, Cash Equivalents and Short-Term Investments5.64B5.44B6.03B3.18B1.36B1.06B
Total Debt4.03B5.84B3.93B623.41M4.69B4.95B
Total Liabilities5.72B8.39B5.49B1.13B6.22B6.20B
Stockholders Equity14.51B15.44B13.56B11.69B3.66B2.94B
Cash Flow
Free Cash Flow-403.95M-2.34B-674.22M292.26M399.24M452.40M
Operating Cash Flow1.30B2.68B2.53B1.15B1.17B1.37B
Investing Cash Flow-1.73B-4.65B-2.09B-758.89M-1.04B-852.46M
Financing Cash Flow-231.75M1.60B3.01B1.28B175.00M322.02M

Jupiter Life Line Hospitals Ltd. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1542.60
Price Trends
50DMA
1267.30
Positive
100DMA
1286.25
Positive
200DMA
1375.24
Negative
Market Momentum
MACD
22.73
Negative
RSI
63.11
Neutral
STOCH
77.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JLHL, the sentiment is Positive. The current price of 1542.6 is above the 20-day moving average (MA) of 1282.07, above the 50-day MA of 1267.30, and above the 200-day MA of 1375.24, indicating a neutral trend. The MACD of 22.73 indicates Negative momentum. The RSI at 63.11 is Neutral, neither overbought nor oversold. The STOCH value of 77.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:JLHL.

Jupiter Life Line Hospitals Ltd. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
₹32.92B20.460.96%9.30%14.06%
66
Neutral
₹88.99B43.300.14%18.88%0.25%
65
Neutral
₹43.33B31.330.16%15.40%19.65%
63
Neutral
₹83.15B36.2336.20%27.59%
62
Neutral
₹97.61B875.3316.15%-67.50%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
50
Neutral
₹18.42B310.390.59%4.93%-75.50%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IN:JLHL
Jupiter Life Line Hospitals Ltd.
1,349.30
-84.74
-5.91%
IN:ARTEMISMED
Artemis Medicare Services Ltd.
287.65
8.85
3.17%
IN:HCG
HealthCare Global Enterprises Ltd.
656.70
126.38
23.83%
IN:INDRAMEDCO
Indraprastha Medical Corporation Limited
364.60
-72.82
-16.65%
IN:SHALBY
Shalby Ltd.
173.55
-26.20
-13.12%
IN:YATHARTH
Yatharth Hospital and Trauma Care Services Limited
820.10
306.60
59.71%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 19, 2026